Catherine Creticos
Infectious Disease · Chicago, ILNPI 1356370233
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $248,486 of the $335,131 with a category attached, or 74.1%. Viiv Healthcare Company accounts for 70.0% of it on its own, with 19 other manufacturers making up the rest. Among infectious disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 782 payments — averaging $428.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$235K
- Gilead$87K
- Theratechnologies Inc.$10K
- GSK$1K
- Merck$706
- Johnson & Johnson$642
- plus $1K from 14 others
Across 243 payments — averaging $5515.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$734K
- Merck$392K
- Viiv Healthcare Company$157K
- AbbVie$58K
- Abbott$332
What the payments were for
- Consulting fees$60,99018%
- Speaking & faculty fees$248,48674%
- Travel & lodging$9,0703%
- Food & beverage$16,3795%
- Education$2060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 407 | $234,548 |
| Gilead | 211 | $87,252 |
| Theratechnologies Inc. | 33 | $9,635 |
| GSK | 10 | $1,002 |
| Merck | 34 | $706 |
| Johnson & Johnson | 29 | $642 |
| Napo Pharmaceuticals Inc | 24 | $398 |
| Amgen | 3 | $164 |
| EMD Serono, Inc. | 7 | $133 |
| Janssen Products, LP | 2 | $128 |
| E.r. Squibb & Sons, L.L.C. | 1 | $116 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| AbbVie | 3 | $68 |
| Dynavax Technologies Corporation | 4 | $44 |
| Lundbeck LLC | 2 | $43 |
| Novo Nordisk | 2 | $40 |
| Pfizer | 2 | $39 |
| Janssen Scientific Affairs, LLC | 1 | $34 |
| Exact Sciences | 1 | $24 |
| Vyera Pharmaceuticals, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$335,131 in reported general payments places this provider in the 95th percentile of 368 infectious disease providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 71 | $305,885 |
| TrogarzoIbalizumab-Uiyk | 27 | $292,823 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 62 | $262,883 |
| SerostimSomatropin | 12 | $243,947 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 30 | $166,165 |
| PrezcobixDarunavir/Cobicistat | 63 | $159,681 |
| DovatoDolutegravir Sodium/Lamivudine | 35 | $109,425 |
| RukobiaFostemsavir Tromethamine | 12 | $107,546 |
| TivicayDolutegravir Sodium | 32 | $101,835 |
| DescovyEmtricitabine/Tenofov Alafenam | 25 | $78,546 |
| IsentressRaltegravir Potassium | 27 | $56,764 |
| JulucaDolutegravir/Rilpivirine | 13 | $52,711 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 12 | $37,888 |
| MytesiCrofelemer | 11 | $26,469 |
| Isentress HdRaltegravir Potassium | 11 | $25,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadGenvoya, Biktarvy, Descovy | $87,252 | $647,314158 claims |
| Viiv Healthcare CompanyDovato, Rukobia, Tivicay, Juluca | $234,548 | $371,51792 claims |
| Theratechnologies Inc.Trogarzo | $9,635 | $292,82327 claims |
| EMD Serono, Inc.Serostim | $133 | $243,94712 claims |
| Janssen Products, LPSymtuza | $128 | $166,16530 claims |
| Johnson & JohnsonPrezcobix | $642 | $159,68163 claims |
| MerckIsentress, Delstrigo, Isentress Hd | $706 | $120,25950 claims |
| Napo Pharmaceuticals IncMytesi | $398 | $26,46911 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $98 | $22,75216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 368 infectious disease providers in Illinois.
Other infectious disease in Chicago
- Frank PalellaChicago$987K
- Babafemi TaiwoChicago$292K
- Beverly ShaChicago$202K
- Chad ZawitzChicago$193K
- Nancy GlickChicago$186K
- Kamaljit SinghChicago$138K
- James SullivanChicago$100K
- Gregory HuhnChicago$99K
- Maximo BritoChicago$75K
- Aniruddha HazraChicago$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.